Key Points
- Director purchase: Adtalem director Michael Malafronte bought 1,200 shares on March 3 at an average price of $97.97, a $117,564 transaction disclosed in an SEC Form 4.
- Stock and analyst outlook: CVSA traded down to $100.05 (‑2.0%) with a market cap of $3.45B and a P/E of 14.69, while analysts have a consensus Buy rating and an average price target of $170.00.
- Recent results: In the latest quarter Adtalem reported $2.43 EPS on $503.39M revenue, with a net margin of 13.41% and return on equity of 20.24%.
Adtalem Global Education Inc. (NYSE:CVSA - Get Free Report) Director Michael Malafronte purchased 1,200 shares of the firm's stock in a transaction that occurred on Tuesday, March 3rd. The shares were bought at an average price of $97.97 per share, for a total transaction of $117,564.00. Following the acquisition, the director directly owned 1,200 shares in the company, valued at $117,564. This trade represents a ∞ increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this link.
Adtalem Global Education Stock Down 2.0%
NYSE CVSA traded down $1.99 on Friday, hitting $100.05. 82,221 shares of the stock were exchanged, compared to its average volume of 446,387. The company has a quick ratio of 0.68, a current ratio of 0.68 and a debt-to-equity ratio of 0.37. Adtalem Global Education Inc. has a 52-week low of $86.26 and a 52-week high of $156.26. The firm has a market capitalization of $3.45 billion, a price-to-earnings ratio of 14.69, a PEG ratio of 0.85 and a beta of 0.72.
Adtalem Global Education (NYSE:CVSA - Get Free Report) last released its earnings results on Wednesday, January 28th. The company reported $2.43 earnings per share (EPS) for the quarter. Adtalem Global Education had a net margin of 13.41% and a return on equity of 20.24%. The firm had revenue of $503.39 million during the quarter.
Analysts Set New Price Targets
CVSA has been the topic of several recent analyst reports. Weiss Ratings began coverage on Adtalem Global Education in a report on Wednesday, February 25th. They issued a "hold (c+)" rating on the stock. Barrington Research reaffirmed an "outperform" rating and issued a $170.00 price objective on shares of Adtalem Global Education in a research report on Monday. Finally, Zacks Research upgraded Adtalem Global Education from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, February 24th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has assigned a Hold rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Buy" and an average target price of $170.00.
Check Out Our Latest Stock Report on Adtalem Global Education
About Adtalem Global Education
(
Get Free Report)
Adtalem Global Education (NYSE: CVSA) is a provider of higher education and workforce solutions focused primarily on programs that prepare students for professional careers in healthcare, medicine, veterinary medicine and related fields. The company operates campus-based and online degree programs, continuing professional education, clinical training and exam-preparation offerings designed to support students seeking licensure and employment in regulated professions.
Adtalem’s portfolio includes institution brands that deliver undergraduate, graduate and professional training across nursing, medicine, veterinary medicine and allied health disciplines.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
